Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Meningeal Neoplasms 1Meningeal Carcinomatosis 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Pemetrexed 5Topotecan 3Dexamethasone 3Bevacizumab 3osimertinib 2Vitamin B 12 2Trastuzumab 2Spinal Puncture 2Radiotherapy 2Methotrexate 2Folic Acid 2Cytarabine 2Busulfan 2trioctyl phosphine oxide 1trastuzumab deruxtecan 1tipifarnib 1merphos 1mafosfamide 1immunotoxin LMB-7 1epothilone B 1avelumab 1aflutinib 1XL647 1Transplantation, Autologous 1Temozolomide 1Rituximab 1Referral and Consultation 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Mental Status and Dementia Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Meningeal Carcinomatosis × mafosfamide × Clear all
NCT00031928 2015-04-30

Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors

National Cancer Institute (NCI)

Phase 1 Completed
3,000 enrolled
CNS

Central Nervous System Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡